These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 8447359)

  • 61. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ovarian function during low-dose oral contraceptive use.
    Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
    Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Coagulation effects of oral contraception.
    Bonnar J
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1042-8. PubMed ID: 2960241
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol.
    Lammers P; op ten Berg M
    Acta Obstet Gynecol Scand; 1991; 70(6):497-500. PubMed ID: 1837199
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
    Nader S; Riad-Gabriel MG; Saad MF
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
    Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
    Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system.
    Spona J; Feichtinger W; Kindermann C; Schneider B; Mellinger U; Walter F; Moore C; Gräser T
    Contraception; 1997 Aug; 56(2):67-75. PubMed ID: 9315414
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood.
    Inauen W; Stocker G; Haeberli A; Straub PW
    Contraception; 1991 May; 43(5):435-46. PubMed ID: 1833126
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
    Walling M
    Contraception; 1992 Oct; 46(4):313-26. PubMed ID: 1486770
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect on blood coagulation and fibrinolysis in women using norethisterone or a combination of ethinyloestradiol and quingestianol.
    Korsan-Bengtsen K; Larsson B
    Gynecol Obstet Invest; 1978; 9(6):312-8. PubMed ID: 754993
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
    Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Archer DF; Timmer CJ; Lammers P
    Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.